Company intelligence / Profile preview

PeptiGrowth Inc.

Ownership: Private
Development stage: Commercial

Overview

PeptiGrowth has successfully developed and launched multiple synthetic peptide alternatives to growth factors, including FGF2 Alternative Peptide (FGFR1c agonist) in October 2024 and KGF Alternative Peptide (FGFR2b agonist) in April 2025[1].

Modalities: Synthetic peptides
Industry: Chemicals & Materials

Drug pipeline

4 assets

PG-001

Commercial

3 more assets in the full pipeline.

Request access →

Partnerships

Orizuru Therapeutics, Inc.[5][6]

Beyond the preview

Go deeper on PeptiGrowth Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PeptiGrowth Inc..

Explore the full profile